Clinical Scorecard: Case Study: Rapid Development of Euglycemic Diabetic Ketoacidosis After Initiation of Henagliflozin in a Treatment-Naive Individual
At a Glance
Category
Detail
Condition
Euglycemic Diabetic Ketoacidosis (euDKA)
Key Mechanisms
SGLT2 inhibitor-induced glucosuria and reduced plasma glucose concentrations leading to metabolic acidosis and ketonemia.
Target Population
Treatment-naive patients with newly diagnosed type 2 diabetes.
Care Setting
Emergency department management of acute metabolic complications.
Key Highlights
Severe euDKA occurred within 4 days of SGLT2 inhibitor initiation.
Precipitating factor was metformin-induced gastrointestinal symptoms.
Patient presented with high-anion-gap metabolic acidosis and ketonemia.
Management included intravenous dextrose, insulin infusion, and fluid resuscitation.
No recurrence of symptoms at 4-week follow-up.
Guideline-Based Recommendations
Diagnosis
Recognize euDKA characterized by metabolic acidosis and ketonemia with plasma glucose <11.1 mmol/L.
Management
Initiate intravenous dextrose and insulin infusion for euDKA treatment.
Monitoring & Follow-up
Monitor for gastrointestinal symptoms and educate on sick-day management.
Risks
Increased risk of euDKA in treatment-naive patients due to routine adverse effects.
Patient & Prescribing Data
40-year-old woman with newly diagnosed type 2 diabetes.
Combination therapy initiated with metformin, henagliflozin, and chiglitazar.
Clinical Best Practices
Provide standardized diabetes self-management education.
Implement stepwise drug initiation in treatment-naive patients.
Schedule early follow-up to monitor for adverse effects.
